Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity		
Sumatra Copper & Gold plc		

ABN

14 136 694 267

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- +Class of +securities issued or to be issued
- 1. CHESS Depository Interests (CDIs) and underlying fully paid ordinary shares.
- 2. CHESS Depository Interests (CDIs).
- Number of *securities issued or to be issued (if known) or maximum number which may be issued
- 1. 560,996,901 CDIs and underlying fully paid ordinary shares.
- 2. 1,217,006 CDIs on conversion of 1,217,006 fully paid ordinary shares from the UK register.
- Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)

CHESS Depository Interests (CDIs) each representing a beneficial interest in a Fully Paid Ordinary Share.

⁺ See chapter 19 for defined terms.

4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:


- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Yes - CHESS Depository Interests (CDIs). Underlying Fully Paid Ordinary Shares are not quoted.

- 5 Issue price or consideration
- 1. A\$0.023 per CDI.
- 2. N/A conversion of fully paid ordinary shares from the UK register.
- 6 Purpose of the issue
 (If issued as consideration for
 the acquisition of assets, clearly
 identify those assets)
- 1. Placement of 150,530,591 CDIs at a price of A\$0.023 per CDI for gross proceeds of approximately A\$3.46 (US\$2.60 million at an exchange rate of 0.7501) as announced on 27 January 2017.

In accordance with the terms of the Amended Facility the Company issued 410,466,310 CDIs as follows:

- 234,751,309 CDIs issued as consideration for the termination of 250,597,351 warrants in the Company at the Issue Price of A\$0.023 per CDI for a value of A\$5.40 million (US\$4.05 million at an exchange rate of 0.7501); and
- 175,715,001 CDIs issued as payment for outstanding redemption premium (accrued through a deferral of a portion of the interest rate), under the senior secured debt facility, at the Issue Price of A\$0.023 per CDI for a value of approximately A\$4.04 million (US\$3.03 million at an exchange rate of 0.7501). 1,825,143 CDIs were issued under the Company's existing Listing Rule 7.1 capacity.
- 2. Conversion of unquoted fully paid ordinary shares to quoted CDIs.



⁺ See chapter 19 for defined terms.

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

30 January 2017.		

8 Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)

Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

Number	+Class
1,271,949,083	CHESS Depository
	Interests (CDIs)
Number	+Class
1,271,949,083	Fully paid ordinary
	shares underlying
	1,271,949,083 CDIs.
1,500,000	Options exercisable
-,,,	at \$0.25 on or before
	14/6/17.
_	
44,260,914	Warrants exercisable
	at \$0.06 each on or
	before 7/4/17.
17,074,171	Warrants exercisable
	at \$0.057 each on or
	before 7/8/17.
7,000,000	Convertible notes;
7,000,000	A\$0.057; 12/11/2017.
	Note - 250,597,351
	warrants exercisable
	at \$0.057 each on or
	before 12/11/17 have been cancelled in
	accordance with
	shareholder approval
	on 13 December 2016.
)
	7,500,000
	Performance Rights
	(project-based) have
	lapsed as their
	performance conditions were not
	met.
	met.

10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A
Part	2 - Pro rata issue	
11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities will be offered	
14	⁺ Class of ⁺ securities to which the offer relates	
15	⁺ Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	

Appendix 3B Page 5 04/03/2013

⁺ See chapter 19 for defined terms.

22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do security holders sell their entitlements <i>in full</i> through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	
32	How do security holders dispose of their entitlements (except by sale through a broker)?	
33	⁺ Issue date	

		Iotation of securities Complete this section if you are applying for quotation of securities
34	Type o	of *securities ne)
(a)		+Securities described in Part 1
(b)		All other ⁺ securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
Entiti	es that	have ticked box 34(a)
Addit	tional s	securities forming a new class of securities
Tick to docume		you are providing the information or
35		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36		If the +securities are +equity securities, a distribution schedule of the additiona +securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37		A copy of any trust deed for the additional *securities
Entiti	es that	have ticked box 34(b)
38		er of ⁺ securities for which tion is sought
39		of *securities for which ion is sought

⁺ See chapter 19 for defined terms.

40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)		

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before [†]quotation of the [†]securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 31 January 2017

(Company secretary)

Softente

Print name: SUSAN HUNTER

== == == ==

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	708,402,182	
Add the following:		
Number of fully paid ⁺ ordinary securities issued in that 12 month period under an exception in rule 7.2	30/01/2017 – 559,171,758 CDIs approved at the General Meeting of Shareholders held on 13 December 2016.	
Number of fully paid ⁺ ordinary securities issued in that 12 month period with shareholder approval		
Number of partly paid ⁺ ordinary securities that became fully paid in that 12 month period		
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	Nil	
"A"	1,267,573,940	

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	190,136,091	
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule	
 Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued: Under an exception in rule 7.2 Under rule 7.1A With security holder approval under rule 7.1 or rule 7.4 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	18/2/2016 – 2,550,000 CDIs 28/4/2016 – 45,998,583 equivalent CDIs (Issue of US\$2 million convertible notes convertible at A\$0.057). (Exchange rate per RBA A\$1 : US\$0.7628) 30/1/2017 - 1,825,143 CDIs.	
"C"	50,373,726	
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining	
"A" x 0.15	190,136,091	
Note: number must be same as shown in Step 2		
Subtract "C"	50,373,726	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	139,762,365	
	[Note: this is the remaining placement capacity under rule 7.1]	

⁺ See chapter 19 for defined terms.

Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	1,267,573,940	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	126,757,394	
7.1A that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	-	
or agreed to be issued in that 12 month	-	

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	126,757,394	
Note: number must be same as shown in Step 2		
Subtract "E"	-	
Note: number must be same as shown in Step 3		
Total ["A" x 0.10] – "E"	126,757,394	
	Note: this is the remaining placement capacity under rule 7.1A	

⁺ See chapter 19 for defined terms.